Incyte (INCY) EPS (Weighted Average and Diluted) (2010 - 2026)

Incyte has reported EPS (Weighted Average and Diluted) for 17 years, with the latest figure at $1.47 in Q1 2026.

• For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 83.75% year-over-year to $1.47; the trailing twelve-month figure through Mar 2026 stood at $7.08 (up 2732.0% YoY), and the FY2025 full-year result was $6.41, up 4173.33% from the prior year.
• EPS (Weighted Average and Diluted) for Q1 2026 stood at $1.47, up from $1.46 in the prior quarter.
• The five-year high for EPS (Weighted Average and Diluted) was $2.11 in Q3 2025, with the low at -$2.04 in Q2 2024.
• Historically, EPS (Weighted Average and Diluted) has averaged $0.72 across 5 years, with a median of $0.76 in 2023.
• The largest YoY upside for EPS (Weighted Average and Diluted) was 650.0% in 2024 against a maximum downside of 326.67% in 2024.
• Incyte's EPS (Weighted Average and Diluted) stood at $0.12 in 2022, then surged by 641.67% to $0.89 in 2023, then grew by 6.74% to $0.95 in 2024, then surged by 53.68% to $1.46 in 2025, then grew by 0.68% to $1.47 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $1.47 (Q1 2026), $1.46 (Q4 2025), and $2.11 (Q3 2025), per Business Quant data.